The METG1090A mutation was identified by next‐generation sequencing in tumour biopsies collected from a patient with a MET fusion‐positive NSCLC that was progressing on crizotinib, while the METY1230S substitution was found in a treatment naïve RCC. This evidence concerns the gene MET and neoplasm.